Lotus Pharmaceutical Co (TPE:1795) Piotroski F-Score: 4 (As of Jun. 28, 2026) — 33% Below Median


TPE:1795 Lotus Pharmaceutical Co Ltd TPE:1795
76 GF Score
Price NT$183.00
GF Value NT$441.58
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lotus Pharmaceutical Co Piotroski F-Score?

Lotus Pharmaceutical Co TPE:1795 -3.17% 76 Piotroski F-Score is 4 as of Jun. 28, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates TPE:1795 with a GF Score™ of 76/100 and a GF Value™ of NT$441.58 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 978 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks worse than 60.74% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lotus Pharmaceutical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Lotus Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

TPE:1795' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Lotus Pharmaceutical Co was 7. The lowest was 4. And the median was 6.

Lotus Pharmaceutical Co  (TPE:1795) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Lotus Pharmaceutical Co Piotroski F-Score Related Terms


Lotus Pharmaceutical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Lotus Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Pharmaceutical Co Piotroski F-Score Chart

Lotus Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 5.00 6.00 4.00

Lotus Pharmaceutical Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 8.00 6.00 4.00

TPE:1795 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lotus Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Lotus Pharmaceutical Co's Piotroski F-Score falls into.


TPE:1795
76GF Score
Lotus Pharmaceutical Co Ltd TPE:1795
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was 1435.431 + 728.263 + 1434.709 + 1121.65 = NT$4,720 Mil.
Cash Flow from Operations was 2728.893 + 931.407 + 2472.509 + 1349.17 = NT$7,482 Mil.
Revenue was 4729.784 + 4747.025 + 4770.699 + 6261.966 = NT$20,509 Mil.
Gross Profit was 2915.302 + 2793.143 + 2734.497 + 3463.727 = NT$11,907 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was
(40101.143 + 40671.506 + 38164.131 + 39599.546 + 106153.931) / 5 = NT$52938.0514 Mil.
Total Assets at the begining of this year (Dec24) was NT$40,101 Mil.
Long-Term Debt & Capital Lease Obligation was NT$43,166 Mil.
Total Current Assets was NT$26,453 Mil.
Total Current Liabilities was NT$16,879 Mil.
Net Income was 1036.296 + 1331.57 + 1565.111 + 1132.533 = NT$5,066 Mil.

Revenue was 4198.144 + 4742.928 + 5234.204 + 4408.951 = NT$18,584 Mil.
Gross Profit was 2303.495 + 2878.991 + 3315.5 + 2426.09 = NT$10,924 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was
(32991.589 + 34286.966 + 34637.805 + 37234.497 + 40101.143) / 5 = NT$35850.4 Mil.
Total Assets at the begining of last year (Dec23) was NT$32,992 Mil.
Long-Term Debt & Capital Lease Obligation was NT$8,578 Mil.
Total Current Assets was NT$18,098 Mil.
Total Current Liabilities was NT$8,438 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lotus Pharmaceutical Co's current Net Income (TTM) was 4,720. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lotus Pharmaceutical Co's current Cash Flow from Operations (TTM) was 7,482. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=4720.053/40101.143
=0.1177037

ROA (Last Year)=Net Income/Total Assets (Dec23)
=5065.51/32991.589
=0.15353944

Lotus Pharmaceutical Co's return on assets of this year was 0.1177037. Lotus Pharmaceutical Co's return on assets of last year was 0.15353944. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Lotus Pharmaceutical Co's current Net Income (TTM) was 4,720. Lotus Pharmaceutical Co's current Cash Flow from Operations (TTM) was 7,482. ==> 7,482 > 4,720 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=43166.077/52938.0514
=0.81540736

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=8577.591/35850.4
=0.23926068

Lotus Pharmaceutical Co's gearing of this year was 0.81540736. Lotus Pharmaceutical Co's gearing of last year was 0.23926068. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=26452.718/16878.826
=1.56721315

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=18098.279/8438.124
=2.14482259

Lotus Pharmaceutical Co's current ratio of this year was 1.56721315. Lotus Pharmaceutical Co's current ratio of last year was 2.14482259. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Lotus Pharmaceutical Co's number of shares in issue this year was 262.408. Lotus Pharmaceutical Co's number of shares in issue last year was 264.767. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=11906.669/20509.474
=0.58054483

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=10924.076/18584.227
=0.58781439

Lotus Pharmaceutical Co's gross margin of this year was 0.58054483. Lotus Pharmaceutical Co's gross margin of last year was 0.58781439. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=20509.474/40101.143
=0.51144363

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=18584.227/32991.589
=0.56330197

Lotus Pharmaceutical Co's asset turnover of this year was 0.51144363. Lotus Pharmaceutical Co's asset turnover of last year was 0.56330197. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+0+1+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lotus Pharmaceutical Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Lotus Pharmaceutical Co (TPE:1795) has a Piotroski F-Score of 4 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lotus Pharmaceutical Co and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Lotus Pharmaceutical Co's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #594 out of 978 companies in the Drug Manufacturers industry, placing it in the top 60.7%.
Is Lotus Pharmaceutical Co's Piotroski F-Score too high?
Lotus Pharmaceutical Co's current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Lotus Pharmaceutical Co's value of 4 is 20% below this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #594 out of 978 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lotus Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #594 out of 978 companies for Piotroski F-Score. This places Lotus Pharmaceutical Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Lotus Pharmaceutical Co's value of 4 is 20% below this benchmark. Historically, Lotus Pharmaceutical Co's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Lotus Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$441.58, compared to a current price of NT$183.00 — trading 58.6% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Lotus Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Piotroski F-Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?

Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$183.00 is trading 58.6% below its estimated GF Value™ of NT$441.58. GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for TPE:1795:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: NT$441.58 vs. price of NT$183.00 (58.6% below fair value)
  • GF Score™: 76/100 with 4 warning signs
  • Industry Position: 20% below the Drug Manufacturers median (#594 of 978)

No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lotus Pharmaceutical Co Business Description

Address Song Ren Road, No. 277, 17th Floor, Xin Yi District, Taipei, TWN, 11046
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
76GF Score

Get the complete analysis for TPE:1795

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$183.00
Price
NT$441.58
GF Value